Menu

Blog

Archive for the ‘neuroscience’ category: Page 131

Feb 20, 2024

Electronic music appears to alter our state of consciousness

Posted by in categories: media & arts, neuroscience

Listening to electronic music makes neurons in our brain fire in time with the beat, which appears to alter our reaction time and sense of unity.

By Conor Feehly

Feb 20, 2024

A Sprinkle of Gold Dust Could Help Reverse Symptoms of Parkinson’s Disease

Posted by in categories: biotech/medical, nanotechnology, neuroscience

Scientists are investigating whether an oral drug sprinkled with gold nanoparticles could one day treat neurodegenerative diseases like Parkinson’s and multiple sclerosis.

The experimental medicine, called CNM-Au8, has now shown success in boosting the brain’s metabolism in phase II clinical trials.

Research on the safety and efficacy of the daily drug is still ongoing, but the initial results have researchers hopeful. The medicine contains suspended nanoparticles of gold that can apparently pass the blood-brain barrier and improve energy supply to neurons, preventing their decline.

Feb 20, 2024

Elon Musk shares update on Neuralink’s first human patient

Posted by in categories: biotech/medical, computing, Elon Musk, neuroscience

Elon Musk shared an update on Neuralink’s first human patient and their experience with the N1 chip.

The first human Neuralink patient seems to have made a full recovery with no ill effects and is able to control the mouse around the screen just by thinking, said Elon Musk during an apparent on X Spaces.

Musk added that Neuralink continuously observes the patient’s ability to use the N1 brain implant. The patient is currently tasked to click on the mouse button as often as possible.

Feb 20, 2024

New technique for revealing genetic repeats yields surprising insights into Huntington’s disease

Posted by in categories: biotech/medical, genetics, neuroscience

Neurodegenerative diseases are among the most complex human ailments, and their exact causes and mechanisms are the subject of ongoing research and debate. When it comes to Huntington’s disease, steadily accumulating evidence over the past 30 years has led to a model of molecular events that explains several key features of the disease, including why it has an earlier onset in some people and why it causes symptoms such as involuntary movements and mood swings.

But two new complementary papers from The Rockefeller University suggest that this may not be the whole story.

Huntington’s is caused by somatic CAG expansions in which a triplet repeat of DNA bases in a mutated Huntingtin (mHTT) gene increase in number throughout life, leading to . As described in Nature Genetics and in Neuron, the Rockefeller scientists used a custom technique to reveal that these genetic repeats are unstable, and likely producing more toxic proteins, only in select brain . Moreover, some cells they studied proved surprisingly resilient to CAG repeat expansion.

Feb 20, 2024

Neuralink’s first human patient able to control mouse through thinking, Musk says

Posted by in categories: biotech/medical, computing, Elon Musk, neuroscience

Feb 20 (Reuters) — The first human patient implanted with a brain-chip from Neuralink appears to have fully recovered and is able to control a computer mouse using their thoughts, the startup’s founder Elon Musk said late on Monday.

“Progress is good, and the patient seems to have made a full recovery, with no ill effects that we are aware of. Patient is able to move a mouse around the screen by just thinking,” Musk said in a Spaces event on social media platform X.

Musk said Neuralink was now trying to get as many mouse button clicks as possible from the patient.

Feb 20, 2024

How to detect the deadliest form of cancer

Posted by in categories: biotech/medical, health, neuroscience

Lung cancer is the deadliest of cancers. Screening could save thousands of lives, so why is it not the norm?

https://econ.st/2VAzFNX

Continue reading “How to detect the deadliest form of cancer” »

Feb 20, 2024

New research offers hope to those affected by aggressive brain cancer

Posted by in categories: biotech/medical, life extension, neuroscience

New research from the University of Sussex holds promise for extending life expectancy and enhancing treatment options for a common and aggressive brain cancer affecting thousands in the UK annually and hundreds of thousands globally.

Published in the Journal of Advanced Science, the study revealed that the protein PANK4, previously overlooked, can hinder cancer cells’ response to chemotherapy in glioblastoma, an aggressive form of brain cancer and if the protein is removed, cancer cells respond better to the main chemotherapy drug used globally for the treatment of glioblastoma.

Continue reading “New research offers hope to those affected by aggressive brain cancer” »

Feb 19, 2024

New genetic therapy shows promise for motor neuron disease and frontotemporal dementia

Posted by in categories: biotech/medical, genetics, neuroscience

Macquarie University neuroscientists have developed a single-dose genetic medicine that has been proven to halt the progression of both motor neuron disease (MND) and frontotemporal dementia (FTD) in mice—and may even offer the potential to reverse some of the effects of the fatal diseases.

It may also hold opportunities for treating more common forms of dementia, such as Alzheimer’s disease, which is the second most common cause of death in Australia after heart disease.

The new treatment, dubbed CTx1000, targets pathological build-ups of the protein TDP-43 in cells in the brain and spinal cord.

Feb 19, 2024

Risk Factors for Death After Neurologic Immune-Related Adverse Events

Posted by in categories: biotech/medical, neuroscience

Neurologic immune-related adverse events (nirAEs) following immune checkpoint inhibitor therapy for cancer are frequent and varied; a recent study identified risk factors for death after nirAEs.


Recent cohort studies have demonstrated that neurologic immune-related adverse events (nirAEs) following immune checkpoint inhibitor (ICI) therapy for cancer are frequent, varied, and associated with higher overall survival (NEJM JW Neurol Sep 29 2023 and Neurology 2023; 101:e2472). Researchers conducted a retrospective cohort study of consecutive patients referred to a tertiary center during a 5-year period to characterize the clinical features of nirAEs and identify predictors of ICI response and survival.

The researchers identified 64 patients with confirmed nirAEs, 81% involving the central nervous system (CNS). The vast majority of CNS nirAE patients had encephalopathy, of which 73% were neither seropositive for well-characterized neural autoantibodies, nor had a distinctive encephalitis syndrome, nor had evidence of CNS inflammatory changes. The most common peripheral nervous system (PNS) syndrome was myasthenia and myositis (with or without myocarditis) overlap syndrome. Only 17% of PNS nirAE patients were seropositive. Steroids were given to 91% of nirAE patients after a median of 90 days of symptoms, and 48% received additional immunotherapy. At 1-month follow-up, 72% of nirAE patients showed improvement, 9% had worsened, and 17% had died. Among the 53 patients who survived the first month, median follow-up was 6 months; during follow-up, 30% died, most commonly of cancer progression or cancer-related complications. Death was associated with lung cancer (hazard ratio, 2.

Continue reading “Risk Factors for Death After Neurologic Immune-Related Adverse Events” »

Feb 19, 2024

To appreciate music, the human brain listens and learns to predict

Posted by in categories: media & arts, neuroscience

What is happening in the cerebral cortex when someone hears a melody?


Music has been central to human cultures for tens of thousands of years, but how our brains perceive it has long been shrouded in mystery.

Continue reading “To appreciate music, the human brain listens and learns to predict” »

Page 131 of 1,000First128129130131132133134135Last